First in Human Study of M6223
The main purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), immunogenicity and (if observed) the maximum tolerated dose (MTD) of M6223 as a single agent (Part 1A) for both the every 2 weeks (Q2W) regimen and the every 3 weeks (Q3W) regimen and of M6223 combined with bintrafusp alfa (Part 1B) for Q2W regimen in participants with metastatic or locally advanced solid unresectable tumors.
Metastatic Solid Tumors
DRUG: M6223|DRUG: Bintrafusp alfa|DRUG: M6223
Part 1A and 1B: Occurrence of Dose Limiting Toxicities (DLTs) During the DLT Observation Period (28 Days), Day 1 to Day 28|Part IA and IB: Occurrence of Treatment-Emergent Adverse Events (TEAEs) and Treatment Related Adverse Events (TRAEs) According to the National Cancer Institute Common Terminology Criteria of Adverse Events (NCI-CTCAE) version 5, Time from first study drug administration to final assessment at end of safety follow-up visit (up to a maximum of approximately 2 years)|Part IA and IB: Occurrence of Treatment-Emergent Adverse Events (TEAEs) as per Severity and Deaths, Time from first study drug administration to final assessment at end of safety follow-up visit (up to a maximum of approximately 2 years)|Part IA and IB: Occurrence of Clinically Significant Change From Baseline in Clinical Laboratory Measures, Time from baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 2 years)|Part IA and IB: Occurrence of Clinically Significant Change From Baseline in Electrocardiogram Findings, Time from baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 2 years)|Part IA and IB: Occurrence of Clinically Significant Change From Baseline in Vital Signs, Time from baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 2 years)|Part IA and IB: Occurrence of Change From Baseline in Eastern Cooperative Oncology Group Performance Status, Time from baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 2 years)
Part 1A and Part 1B: Area Under the Serum Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of M6223, Pre-dose up to 14 days (in Q2W regimen) or 21 days (in Q3W regimen) post-dose of Cycles 1, 2, and 4 (Each cycle is of 14 days in Q2W regimen and each Cycle is of 21 days in Q3W regimen)|Part 1A and Part 1B: Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUC 0-inf) of M6223, Pre-dose up to 14 days (in Q2W regimen) or 21 days (in Q3W regimen) post-dose of Cycles 1, 2, and 4 (Each cycle is of 14 days in Q2W regimen and each Cycle is of 21 days in Q3W regimen)|Part 1A and Part 1B: Area Under Serum Concentration-Time Curve Over a Dosing Interval From Time Zero to Tau (τ) (AUCτ) of M6223, Pre-dose up to 14 days (in Q2W regimen) or 21 days (in Q3W regimen) post-dose of Cycles 1, 2, and 4 (Each cycle is of 14 days in Q2W regimen and each Cycle is of 21 days in Q3W regimen)|Part 1A and Part 1B: Maximum Observed Serum Concentration (Cmax) of M6223, Pre-dose up to 14 days (in Q2W regimen) or 21 days (in Q3W regimen) post-dose of Cycles 1, 2, and 4 (Each cycle is of 14 days in Q2W regimen and each Cycle is of 21 days in Q3W regimen)|Part 1A and Part 1B: Serum Concentration Observed Immediately Before Next Dosing (Ctrough) of M6223, Pre-dose up to 14 days (in Q2W regimen) or 21 days (in Q3W regimen) post-dose of Cycles 1, 2, and 4 (Each cycle is of 14 days in Q2W regimen and each Cycle is of 21 days in Q3W regimen)|Part 1A and Part 1B: Time to Reach Maximum Serum Concentration (Tmax) of M6223, Pre-dose up to 14 days (in Q2W regimen) or 21 days (in Q3W regimen) post-dose of Cycles 1, 2, and 4 (Each cycle is of 14 days in Q2W regimen and each Cycle is of 21 days in Q3W regimen)|Part 1A and Part 1B: Apparent Terminal Half-Life (t1/2) of M6223, Pre-dose up to 14 days (in Q2W regimen) or 21 days (in Q3W regimen) post-dose of Cycles 1, 2, and 4 (Each cycle is of 14 days in Q2W regimen and each Cycle is of 21 days in Q3W regimen)|Part 1A and Part 1B: Elimination Rate Constant (Lambda z) of M6223, Pre-dose up to 14 days (in Q2W regimen) or 21 days (in Q3W regimen) post-dose of Cycles 1, 2, and 4 (Each cycle is of 14 days in Q2W regimen and each Cycle is of 21 days in Q3W regimen)|Part 1B: Maximum Observed Serum Concentration (Cmax) of Bintrafusp alfa, Pre-dose up to 14 days (in Q2W regimen) post-dose of Cycles 1, 2, and 4 (Each cycle is of 14 days in Q2W regimen)|Part 1B: Serum Concentration Observed Immediately Before Next Dosing (Ctrough) of Bintrafusp alfa, Pre-dose up to 14 days (in Q2W regimen) post-dose of Cycles 1, 2, and 4 (Each cycle is of 14 days in Q2W regimen)|Part IA and 1B: Immunogenicity of M6223 Measured by Antidrug Antibody (ADA) Assays, Pre-dose of Day 1 Cycle 1 (Each Cycle is of 14 days in Q2W regimen and 21 days in Q3W regimen) up to end of safety follow-up visit (up to a maximum of 2 years)|Part 1B: Immunogenicity of Bintrafusp alfa Measured by Antidrug Antibody (ADA) Assays, Pre-dose of Day 1 Cycle 1 (Each Cycle is of 14 days in Q2W regimen) up to end of safety follow-up visit (up to a maximum of 2 years)|Part 1A and 1B: Change from Baseline in QT Interval, From Day 1 Cycle 1 (Baseline) up to Day 1 Cycle 7 (Each Cycle is of 14 days in Q2W regimen and 21 days in Q3W regimen)|Part 1A and IB: Best Overall Response According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed as per Investigator, From first study drug administration until documented disease progression or death due to any cause whichever occurs first, (approximately assessed up to 2 years)|Part 1A and 1B: Duration of Response According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed as per Investigator, From first study drug administration until documented disease progression or death due to any cause whichever occurs first, (approximately assessed up to 2 years)|Part 1A and 1B: Time to Tumor Response According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed as per Investigator, From first study drug administration until documented disease progression or death due to any cause whichever occurs first, (approximately assessed up to 2 years)|Part 1A and 1B: Disease Control According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed as per Investigator, From first study drug administration until documented disease progression or death due to any cause whichever occurs first, (approximately assessed up to 2 years)|Part 1A and 1B: Progression-free Survival Time According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed as per Investigator, From first study drug administration until documented disease progression or death due to any cause whichever occurs first, (approximately assessed up to 2 years)|Part 1A and 1B: Overall Survival, Time from first treatment to end of study (planned 12 months after last patient started treatment)
The main purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), immunogenicity and (if observed) the maximum tolerated dose (MTD) of M6223 as a single agent (Part 1A) for both the every 2 weeks (Q2W) regimen and the every 3 weeks (Q3W) regimen and of M6223 combined with bintrafusp alfa (Part 1B) for Q2W regimen in participants with metastatic or locally advanced solid unresectable tumors.